Clinical Trial Update: A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II open-label study of immunoconjugate L-DOS47 in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• L-DOS47

Snippet

Sponsor: Helix BioPharma Corporation | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED